Austria

Austria is a member state of the European Union and therefore operates within the harmonized EU regulatory framework for all health products. The primary regulatory authority is AGES, which acts as the national competent authority under the oversight of the BMSGPK. Pharmaceuticals are governed by the Arzneimittelgesetz (AMG, Medicinal Products Act) and relevant EU directives and regulations, including Regulation (EC) No 726/2004 for centrally authorized products and Directive 2001/83/EC for nationally or mutually recognized products. Medical devices fall under EU Regulation (EU) 2017/745 (MDR) and EU Regulation (EU) 2017/746 (IVDR), with AGES serving as the national market surveillance authority and notified bodies operating under the accreditation framework. Digital health applications may additionally be subject to review under the DiGAV-equivalent national pathway currently under development in Austria, aligned with broader EU digital health strategy initiatives.

For pharmaceutical submissions, Austria accepts applications in the Common Technical Document (CTD) format via the EU eCTD standard through the centralized procedure (EMA), the mutual recognition procedure (MRP), or the decentralized procedure (DCP), in which AGES may act as reference or concerned member state. A local EU-based qualified person for pharmacovigilance (QPPV) and an Austrian or EU-registered marketing authorization holder are mandatory. Product labeling and package leaflets must be provided in German. Recent reforms include the transposition of the EU Health Technology Assessment Regulation (EU) 2021/2282, which Austria is implementing progressively from 2025 onward, harmonizing joint clinical assessments for new oncology products and advanced therapy medicinal products (ATMPs). Post-Brexit adjustments have also reinforced AGES's role in verifying supply-chain compliance and batch release for products previously routed through UK-based entities.

Austria operates a federal system in which health procurement responsibilities are split between the federal government and nine provincial (Laender) governments. The BMSGPK sets overarching health policy and reimbursement frameworks, while actual procurement of pharmaceuticals, medical devices, and diagnostics is largely decentralized to the Laender-level hospital funds (Landesgesundheitsfonds) and individual hospital operators. The main statutory health insurance body, the Dachverband der Sozialversicherungstraeger (umbrella organization of Austrian social insurance institutions), negotiates reimbursement and pricing for outpatient pharmaceuticals through the Erstattungskodex (EKO), Austria's positive reimbursement list, which is divided into the green box (automatic reimbursement), yellow box (restricted reimbursement requiring physician justification), and red box (case-by-case authorization). For hospital products, joint procurement is frequently coordinated through BHAG (Bundesbeschaffung GmbH), Austria's federal procurement agency, and regional hospital consortia that conduct framework tenders in accordance with EU public procurement directives (Directive 2014/24/EU), transposed nationally via the Bundesvergabegesetz (BVergG).

Austria is a high-income OECD country and does not rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi; all procurement is financed through domestic public insurance and taxation revenues or private out-of-pocket expenditure. The private healthcare market is served through pharmacies, private hospitals, and supplementary private health insurance schemes, with products entering via standard EU marketing authorization pathways. There are no formal local manufacturing preference policies mandated in public tenders; however, EU-based manufacturing and supply-chain resilience have gained increased policy attention following COVID-19 disruptions, and Austria participates in EU-level strategic reserve mechanisms (rescEU medical stockpile) and the EU Health Emergency Preparedness and Response Authority (HERA) frameworks. Health technology assessment for reimbursement decisions increasingly incorporates cost-effectiveness and budget-impact analyses, with the HVB (Hauptverband, now Dachverband) applying AMNOG-adjacent negotiation principles for new high-cost therapies.